Search Results | MSF Science Portal

Journal Article

|

Research

Broger T, Koeppel L, Huerga H, Miller P, Gupta-Wright A, et al.

2023-06-01 • Lancet Global Health

BACKGROUND
Sputum is the most widely used sample to diagnose active tuberculosis, but many people living with HIV are unable to produce sputum. Urine, in contrast, is readily availab...

Journal Article

|

Research

Griesel R, Zhao Y, Simmons B, Omar Z, Wiesner L, et al.

2023-05-22 • Lancet HIV

BACKGROUND
The drug-drug interaction between rifampicin and dolutegravir can be overcome by supplemental dolutegravir dosing, which is difficult to implement in high-burden settings....

Journal Article

|

Research

Spies R, Schutz C, Ward A, Balfour A, Shey M, et al.

2022-09-27 • Southern African Journal of HIV Medicine

BACKGROUND
Patients with HIV and drug-resistant tuberculosis (TB) are at high risk of death.

OBJECTIVES
We investigated the association between rifampicin-resistant TB (...

Journal Article

|

Research

Govender NP, Meintjes GA, Mangena PM, Nel J, Potgieter S, et al.

2019-11-08 • Southern African Journal of HIV medicine

Journal Article

|

Letter

Hughes J, Isaakidis P, Andries A, Mansoor H, Cox V, et al.

2015-12-01 • European Respiratory Journal

Journal Article

|

Research

Ford NP, Shubber Z, Meintjes GA, Grinsztejn B, Eholie SP, et al.

2015-08-11 • Lancet HIV

Journal Article

|

Research

Rangaka MX, Wilkinson KA, Seldon R, van Cutsem G, Meintjes GA, et al.

2007-12-07 • American Journal of Respiratory and Critical Care Medicine

RATIONALE: Two forms of the IFN-gamma release assay (IFNGRA) to detect tuberculosis infection are available, but neither has been evaluated in comparable HIV-infected and uninfected pers...

Journal Article

|

Research

Daniels J, Khogali MA, Mohr E, Cox V, Moyo S, et al.

2015-11-10 • PLOS One

SETTING
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co-infection.

OBJECTIVE
To describe time to antiretroviral trea...

Journal Article

|

Research

Osler M, Hilderbrand K, Goemaere E, Ford NP, Smith M, et al.

2018-03-04 • Clinical Infectious Diseases

BACKGROUND
Antiretroviral treatment (ART) has been massively scaled up to decrease human immunodeficiency virus (HIV)-related morbidity, mortality, and HIV transmission. However, des...

Journal Article

|

Research

Ndjeka N, Campbell JR, Meintjes GA, Maartens G, Schaaf HS, et al.

2022-05-02 • Lancet Infectious Diseases

BACKGROUND
There is a need for short and safe all-oral treatment of rifampicin-resistant tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients wi...

Journal Article

|

Commentary

Ford NP, Meintjes GA, Pozniak A, Bygrave H, Hill AM, et al.

2014-11-19 • Lancet Infectious Diseases

For more than two decades, CD4 cell count measurements have been central to understanding HIV disease progression, making important clinical decisions, and monitoring the response to ant...

Journal Article

|

Research

Ismail N, Omar SV, Moultrie H, Bhyat Z, Conradie F, et al.

2021-11-12 • Lancet Infectious Diseases

BACKGROUND
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...

Journal Article

|

Research

Ndjeka N, Hughes J, Reuter A, Conradie F, Enwerem M, et al.

2020-10-01 • International Journal of Tuberculosis and Lung Disease

Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for t...

Journal Article

|

Research

Saranchuk P, Boulle AM, Hilderbrand K, Coetzee D, Bedelu M, et al.

2007-07-01 • South African Medical Journal

OBJECTIVES: To evaluate the diagnostic accuracy of and reduction in diagnostic delay attributable to a clinical algorithm used for the diagnosis of smear-negative pulmonary tuberculosis ...

Journal Article

|

Research

Shroufi A, Govender NP, Meintjes GA, Black JM, Nel J, et al.

2020-06-01 • International Journal of Infectious Diseases

BACKGROUND
Cryptococcal Meningitis (CM) is estimated to cause 181,000 deaths annually; with the majority occurring in Sub Saharan Africa. Flucytosine is recommended by the World Heal...

Journal Article

|

Research

Ndjeka N, Schnippel K, Master I, Meintjes GA, Maartens G, et al.

2018-10-25 • European Respiratory Journal

Background: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a ...

Journal Article

|

Letter

Hughes J, Isaakidis P, Andries A, Mansoor H, Cox V, et al.

2015-04-02 • European Respiratory Journal

Journal Article

|

Research

Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N, et al.

2015-07-19 • International Journal of Tuberculosis and Lung Disease

BACKGROUND
South Africa has a large burden of extensively drug-resistant tuberculosis (XDR-TB); only 15% of XDR-TB patients have successful outcomes.

OBJECTIVE
To descri...

Journal Article

|

Research

Schnippel K, Ndjeka N, Maartens G, Meintjes GA, Master I, et al.

2018-09-01 • Lancet Respiratory Medicine

Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Foll...

Journal Article

|

Letter

Ndjeka N, Conradie F, Meintjes GA, Reuter A, Hughes J, et al.

2020-07-23 • European Respiratory Journal

Rapid adoption of new diagnostic tools, parallel process of research and implementation, decentralisation of services, the use of personal protective equipment, as well as strong partner...

Science Portal

Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant data

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial

Rifampicin resistance and mortality in patients hospitalised with HIV-associated tuberculosis

Southern african HIV clinicians society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update

Linezolid in drug-resistant tuberculosis: haste makes waste

Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis

Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection

Time to ART initiation among patients treated for rifampin-resistant tuberculosis in Khayelitsha, South Africa: Impact on mortality and treatment success

The continuing burden of advanced HIV disease over 10 years of increasing antiretroviral therapy coverage in South Africa

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa a retrospective cohort study

The future role of CD4 cell count for monitoring antiretroviral therapy

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?

Evaluation of a diagnostic algorithm for smear-negative pulmonary tuberculosis in HIV-infected adults

Time to embrace access programmes for medicines: Lessons from the South African flucytosine access programme

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen

Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis

Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study

Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?